Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders, fibrotic diseases, and inflammatory conditions. This page serves as the definitive source for verified corporate developments, offering investors and researchers timely access to essential information.
Find comprehensive coverage of MNOV's clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on lead candidates MN-166 (ibudilast) and MN-001 (tipelukast), patent developments, and collaborative research initiatives with academic institutions.
Key content categories include clinical program updates, FDA communications, intellectual property announcements, and financial disclosures. All materials are sourced directly from company filings and official statements to ensure accuracy.
Bookmark this page for streamlined tracking of MNOV's progress in developing small-molecule therapeutics. Check regularly for updates on pipeline advancements in ALS, multiple sclerosis, and fibrotic disease research.
MediciNova (NASDAQ:MNOV) announced receipt of two milestone payments totaling $4 million from Genzyme, a Sanofi subsidiary. These payments are due to successful achievements in clinical development milestones concerning a gene therapy product utilizing AAV vector technology. This development emphasizes MediciNova's strategic focus on treatments for unmet medical needs, including neurological disorders and fibrotic diseases. The company continues to advance its pipeline with products like MN-166 and MN-001.
MediciNova has announced participation in a fireside chat at the B. Riley Neuroscience Conference on April 29, 2021, at 1:30 p.m. ET. CEO Yuichi Iwaki and VP Geoffrey O'Brien will discuss MN-166 (ibudilast), a treatment for neurological conditions including ALS and multiple sclerosis. MN-166 inhibits pro-inflammatory cytokines and promotes neurotrophic factors, backed by promising preclinical and clinical trial results. The company will also be available for one-on-one meetings during the conference, allowing investors to engage directly.
MediciNova, a biopharmaceutical company trading on NASDAQ under the symbol MNOV, will participate in the UBS Global Healthcare Virtual Conference from May 24-26, 2021. Key executives, including Yuichi Iwaki, MD, PhD, President, and Geoffrey O'Brien, JD/MBA, Vice President, will hold one-on-one meetings with investors. MediciNova is focused on developing novel therapeutics for unmet medical needs, targeting neurological disorders and fibrotic diseases. For more details, visit medicinova.com.
MediciNova, Inc. has announced a partnership with BARDA to repurpose its drug MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung damage. This collaboration falls under BARDA's ReDIRECT program, which provides funding for proof-of-concept studies in preclinical models. MN-166 has shown efficacy in reducing pulmonary injury in animal models and has been administered to over 800 clinical trial participants. The drug is also in late-stage development for several neurological disorders and COVID-19-related ARDS.
MediciNova, a biopharmaceutical company trading as MNOV, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one investor meetings, facilitated by Maxim Group. MediciNova focuses on developing small-molecule therapeutics for diseases such as progressive multiple sclerosis and substance dependence, with key products including MN-166 and MN-001. The conference will feature discussions and presentations from various issuers, enhancing visibility for emerging growth companies.
MediciNova, Inc. has announced the discontinuation of its SARS-CoV-2 vaccine development due to the presence of established vaccines and those in advanced development. This strategic decision aims to redirect resources toward other critical programs with significant unmet medical needs and market potential. MediciNova's focus will now remain on therapies like MN-166 for neurological disorders and MN-001 for treating fibrotic diseases, ensuring its alignment with larger medical opportunities.
MediciNova, a biopharmaceutical company trading under NASDAQ:MNOV, has completed a private placement of $20 million in stock to 3D Opportunity Master Fund. The funding will support three key initiatives: starting a pivotal clinical trial for MN-166 (ibudilast) in glioblastoma, developing an intravenous formulation of MN-166 for ALS patients, and initiating a Phase 2 trial for MN-001 (tipelukast) in NASH. The company aims to address unmet medical needs in various neurological and fibrotic diseases.
MediciNova has announced positive results from a study on MN-001 (tipelukast) in an acute liver injury model. The findings will be presented at The Liver Meeting Digital Experience™ 2020 by researchers from the University of Louisville. MN-001, an orally bioavailable compound, exhibits anti-inflammatory and anti-fibrotic activities, potentially making it viable for treating fibrotic diseases like NASH and IPF. The poster presentation is scheduled for November 13-16, 2020, showcasing the study’s contributions to fibrosis research.
MediciNova, Inc. reported positive clinical findings for MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy (CIPN), as detailed in Cancer Chemotherapy and Pharmacology. A pilot study involving 14 patients revealed that co-treatment with MN-166 improved or stabilized neurotoxic symptoms caused by oxaliplatin. Notably, 10 out of 12 participants showed no worsening of symptoms. Pharmacokinetic analysis indicated MN-166 did not affect oxaliplatin exposure. The results suggest MN-166 may play a significant role in enhancing the quality of life for cancer patients undergoing chemotherapy.
MediciNova, Inc. announced promising results for its intranasal SARS-CoV-2 vaccine prototype using BC-PIV technology, which successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies in mice. The study confirmed high antibody titers against the S1 antigen, indicating potential efficacy in generating immune responses. CEO Yuichi Iwaki expressed optimism about the results and future developments. The BC-PIV platform is designed to administer vaccines intranasally, which could enhance local immunity against COVID-19.
